The neuraminidase inhibitors evidence of harms – in context

"The neuraminidase inhibitors evidence of harms – in context." Infectious Diseases, 48(9), pp. 661–662

Disclosure Statement

TJ has acted as a consultant for Roche (1997-99), GSK (2001-2), Sanofi-Synthelabo (2003), and IMS Health (2013). TJ was a co-recipient with RH of a UK National Institute for Health Research grant for a Cochrane review of neuraminidase inhibitors for preventing and treating influenza. In addition TJ receives royalties from his books published by Il Pensiero Scientifico Editore, Rome and Blackwells. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011-13, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. In 2014 TJ was retained as a scientific adviser to a legal team acting on oseltamivir and retains a potential monetary interest in its outcome. In 2014-16 TJ was a member of three advisory boards for Boerhinger Ingelheim and is holder of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. TJ is a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.